Palbociclib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Palbociclib and local guidelines before prescribing.
CDK4/6 inhibitor
Mechanism
CDK4/6 inhibitor.
Uses
HR-positive HER2-negative breast cancer.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Neutropenia, fatigue, infection, interstitial lung disease.
Interactions
CYP3A4 inhibitors and inducers.
Contraindications and cautions
Pregnancy
Monitoring
FBC
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Caution in severe hepatic impairment
Overdose and reversal
Supportive
Special advice
Weekly FBC initially.
More from the textbook: uses, cautions and other points
- CDK4/6 inhibitors (ER-positive breast cancer - palbociclib, ribociclib, abemaciclib): Neutropenia (usually without infection), ribociclib QT prolongation, abemaciclib diarrhoea.
Oncology: Principles - Aromatase inhibitor or fulvestrant plus a CDK4/6 inhibitor (palbociclib, ribociclib, abemaciclib).
Oncology: Breast and Gynae Cancers - Palbociclib / ribociclib / abemaciclib | CDK4/6 inhibitors with endocrine therapy; neutropenia; ribociclib QT; abemaciclib diarrhoea.
Oncology: Breast and Gynae Cancers - Cyclins bind cyclin-dependent kinases (CDKs) to drive progression; CDK inhibitors (p21, p16, p27) restrain them. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) treat hormone receptor-positive breast cancer.
Cell Biology: Cell cycle, signalling, cell death and stem cells
Where it is discussed in the book
- Oncology: Principles (1 mention)
- Oncology: Breast and Gynae Cancers (2 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)